FDA scientists team “Johnson vaccine” injects a single dose – protects against COVID by 66%.
FDA scientists team – 25 Feb. Daily Mail Reported that scientists and experts at the US Food and Drug Administration (FDA) confirmed that COVID-19 vaccine Developed by Janssen Pharmaceutical Company Affiliated with Johnson & Johnson Company (J&J) Drug industry giant with just one dose to effectively prevent COVID-19 infection In moderate to severe severity at 66 percent.
And that J & J’s vaccine, which is expected to effectively stop the outbreak of the deadly virus in the US, is used only by a single dose. It is safe to use. It also increases protection against mutated infections, which were previously believed to inhibit COVID-19. Brazilian strains were up to 68% and COVID-19, South African strains at 64%.
The final assessment and decision-making process by an independent advisory panel before the FDA will approve the vaccine as an emergency, possibly as early as Friday, Feb. 26 local time.
Johnson & Johnson’s single-dose vaccine is 66 per cent effective at protecting against COVID-19, according to an analysis by U.S. regulators. A panel of independent experts are set to meet Friday to decide whether to approve the vaccine for use in the U.S. ( Johnson & Johnson/AP)
–
Mr. Jeff Scents Coordinator of the COVID-19 Response Agency White House Said during a press conference that if J & J’s vaccine is approved Authorities will be able to allocate 3-4 million doses of the vaccine within the next week. J&J signed a contract with the federal government to produce 100 million doses of the vaccine by June. And the company is working to accelerate production
Efforts to advance the COVID vaccination program in the United States have not been met. After confronting the weather problem And transportation, leading to a significant delay in the vaccination program. To date, about 65 million Americans have received Pfizer-Bion Tech vaccines. Or at least one dose of Moderna, in which this group needs to receive a second dose of the vaccine in order to protect the virus effectively.
For J&A clinical trials of 44,000 volunteers in the United States, Latin America and South Africa. The vaccine was found to inhibit COVID-19. In the United States, the highest at 72 percent, compared with defense efficiency in Latin America at 66 percent and South Africa at 57 percent.
There are even differences depending on the severity of the virus strain. But the results of a single dose of J & J’s vaccine were considered high. It is also a test in patients with severe symptoms. And previous studies have also found no reports of admission or death 28 days after vaccination.
A Johnson & Johnson scientist works in a laboratory during the development and testing of the Janssen coronavirus disease (COVID-19) vaccine candidate in an undated photograph. Johnson & Johnson/Handout via REUTERS
–
FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed Johnson&Johnson logo in this illustration taken, February 9, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
–
Related news:
–
